Sara Rosenbaum told Bloomberg Law that the Supreme Court could decide the case regarding FDA’s approval of the abortion drug mifepristone by determining that the plaintiffs — doctors who don’t prescribe medication abortion — don’t have standing. “This may be an opportunity for the Supreme Court to start setting some ground rules,” she said, noting, “The standing issue is a threat to the proper functioning of courts.”
Abortion Pill Access Threatened as Justices Take Narrow Appeal
December 14, 2023